Biologic response-modifying agents: What is an appropriate phase I–II strategy? S. K. Carter Editorial Pages: 207 - 210
Embryonic antigens and tumor cell cytolysis P. C. JonesN. SidellR. F. Irie Guest Editorials Pages: 211 - 214
Variable expression of histocompatibility antigens on tumor cells W. J. MartinM. Imamura Review Pages: 219 - 223
A unique antigen (sigma) on sézary cells Amanullah KhanSandra L. F. BurtJ. M. Hill Original Articles Pages: 225 - 230
Influence of T-lymphocyte deprivation on the antileukemic effect of bacillus calmette-guérin in vivo L. OlssonP. EbbesenJ. Hesse Original Articles Pages: 231 - 240
Disseminated intravascular coagulation following intravenous Corynebacterium parvum injection in the rat P. W. JohnstonA. W. ThomsonJ. G. Simpson Original Articles Pages: 241 - 247
Immunogenicity alterations induced in isolated Meth A sarcoma surface membranes D. L. McCollester Original Articles Pages: 249 - 256
Systemic administration of Corynebacterium parvum during sensitization to tumor alloantigen-modified response to rechallenge R. I. MurahataJ. Zighelboim Original Articles Pages: 257 - 261
A phase I study of intrapleural Corynebacterium parvum after complete resection of bronchogenic carcinoma A. J. SolanS. E. VoglC. Salazar Original Articles Pages: 263 - 264
Analysis of the effect of periodate oxidation and phenol extraction on the antitumour properties of C. parvum Valentina RIveros-MorenoAnne Niblock Original Articles Pages: 265 - 272
Conversion of skin tests in cancer patients after a short course of treatment with a new immunostimulating compound Jean-Marie LangCathy GironRené Zalisz Letter To The Editors Pages: 273 - 274
